Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GGPS1 | O95749 | 5/20 | 0.33 |
| ▸ | FDPS | P14324 | 5/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2156367 | 0.71 | KISS1R (0.32) | — | |
| SCHEMBL5949707 | 0.71 | EPHX1 (0.48) | EPHX1GAAKCNA5 | |
| SCHEMBL27794042 | 0.71 | EPHX1 (0.44) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL3190326 | 0.70 | EPHX1 (0.61) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL26084965 | 0.69 | EPHX1 (0.42) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL5949703 | 0.69 | EPHX1 (0.50) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL6647158 | 0.68 | EPHX1 (0.41) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL7113835 | 0.67 | TET2 (0.46) | MEN1KMT2A | |
| SCHEMBL7765762 | 0.67 | GABRR1 (0.50) | EPHX1ALDH1A1MEN1GAAKMT2A | |
| SCHEMBL20616625 | 0.67 | EPHX1 (0.48) | EPHX1MEN1GAAKMT2AKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973082-B2 | Substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2011-07-05 | — | — | US | disclosed |
| US-20090215905-A1 | Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors | ANIONA APS (DK) | 2009-08-27 | — | — | US | disclosed |
| US-20090023772-A1 | Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors | NEUROSEARCH A/S (DK) | 2009-01-22 | — | — | US | disclosed |
| EP-1786778-A1 | NOVEL SUBSTITUTED HETEROARYLOXY ALKYLAMINES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-05-23 | — | — | EP | disclosed |
| EP-1784381-A1 | NOVEL SUBSTITUTED ARYLOXY ALKYLAMINES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2007-05-16 | — | — | EP | disclosed |
| WO-2006021564-A1 | NOVEL SUBSTITUTED ARYLOXY ALKYLAMINES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021565-A1 | NOVEL SUBSTITUTED HETEROARYLOXY ALKYLAMINES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215905-A1 | Novel substituted aryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | EPHX1 904/4885ALDH1A1 592/4885GGPS1 3405/4885 |
| US-20090023772-A1 | Novel substituted heteroaryloxy alkylamines and their use as monoamine neurotransmitter re-uptake inhibitors | SLC6A2, SLC18A2, SLC6A3 | EPHX1 911/4885ALDH1A1 1136/4885GGPS1 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.